2022 - IHE

Hofmarcher T, Ramdén V, Lindgren P Samhällsekonomiska kostnader för narkotikabruk i Sverige IHE Rapport 2022:5, IHE, Lund, Sverige
Olofsson S, Althin R, Lindgren P Metod för hälsoekonomisk utvärdering av kognitiva hjälpmedel – En kartläggning av relevanta och accepterade värdeattribut och metoder IHE Rapport 2022:3, IHE, Lund, Sverige
Persson U, Olofsson S, Althin R, Palmborg A, Dorange AC Acceptance and application of a broad population health perspective when evaluating vaccine Vaccine 2022. Epub ahead of print
DOI: 10.1016/j.vaccine.2022.04.009
Löfvendahl S, Norlin JM, Schmitt-Egenolf M. Economic Burden of Generalized Pustular Psoriasis in Sweden: A Population-Based Register Study Psoriasis: Targets and Therapy 2022; 2022(12): 89-98
DOI: https://doi.org/10.2147/PTT.S359011
Ericson O, Hjelmgren J, Sjövall F, Söderberg J, Persson I The Potential Cost and Cost-Effectiveness Impact of Using a Machine Learning Algorithm for Early Detection of Sepsis in Intensive Care Units in Sweden Journal of Health Economics and Outcomes Research 2022;9(1):101-110
DOI: 10.36469/jheor.2022.33951
Norlin J M, Hjalte F, Kruse C, Dodel R, Rosqvist K, Odin P Quality of life and resource utilization-Swedish data from the Care of Late-Stage Parkinsonism (CLaSP) study Acta Neurologica Scandinavica, 2022;145(6):743-752)
DOI: 10.1111/ane.13611
Kotsopoulos N, Connolly M P, Willis M, Nilsson A, Ericsson Å, Baker-Knight J The public economic burden of sub-optimal type-2 diabetes control on tax payors in Sweden: Looking beyond health costs Diabetes, Obesity and Metabolism, 2022 (ePub ahead of print)
DOI: 10.1111/dom.14667
Landmesser U, Lindgren P, Hagstrom E, van Hout B, Villa G, Pemberton-Ross P, Arellano J, Eriksson Svensson M, Sibartie M, Fonarow GC Cost-effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition with evolocumab in patients with a history of myocardial infarction in Sweden European Heart Journal - Quality of Care and Clinical Outcomes, 2022;8(1):31-38
DOI:10.1093/ehjqcco/qcaa072
Norlin J, Hjalte F, Kellerborg K, Odin P Vid Parkinsons sjukdom ökar kostnaderna med sjukdomens svårighetsgrad Neurologi i Sverige nr 1 - 2022, sid 70-74
Eliasson B, Ericsson Å, Fridhammar A, Nilsson A, Persson S, Chubb B Long-Term Cost Effectiveness of Oral Semaglutide Versus Empagliflozin and Sitagliptin for the Treatment of Type 2 Diabetes in the Swedish Setting PharmacoEconomics - Open, 2022 (ePub ahead of print)
DOI: 10.1007/s41669-021-00317-z

Nästa »